
Opinion|Videos|January 6, 2025
An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier promising results by evaluating efficacy, safety, and durability of response in a larger patient population.
Episodes in this series

Video content above is prompted by the following:
- Introduce the phase 2 study of loncastuximab plus rituximab in R/R FL presented at ASH 2024.



















